Contreras-Garza BM. Update on clinical aspects of COPD. N Engl J Med. 2019;381:2484–5.

Article  PubMed  Google Scholar 

Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J. Developing COPD: a 25 year follow up study of the general population. Thorax. 2006;61:935–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hogg JC. Why does airway inflammation persist after the smoking stops? Thorax. 2006;61:96–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rutgers SR, Postma DS, ten Hacken NH, Kauffman HF, van Der Mark TW, Koeter GH, Timens W. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 2000;55:12–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, Kitahara CM, Furr M, Li Y, Kemp TJ, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst. 2014;106:dju294.

Article  PubMed  PubMed Central  Google Scholar 

Wilkinson TM, Patel IS, Wilks M, Donaldson GC, Wedzicha JA. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:1090–5.

Article  PubMed  Google Scholar 

Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, Hiemstra PS, Timens W, Sterk PJ, Mauad T. Relation between duration of smoking cessation and bronchial inflammation in COPD. Thorax. 2006;61:115–21.

Article  CAS  PubMed  Google Scholar 

Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, Grimes MJ, Harms HJ, Tellez CS, Smith TM, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 2002;62:2370–7.

CAS  PubMed  Google Scholar 

Soria JC, Rodriguez M, Liu DD, Lee JJ, Hong WK, Mao L. Aberrant promoter methylation of multiple genes in bronchial brush samples from former cigarette smokers. Cancer Res. 2002;62:351–5.

CAS  PubMed  Google Scholar 

Wang G, Wang R, Strulovici-Barel Y, Salit J, Staudt MR, Ahmed J, Tilley AE, Yee-Levin J, Hollmann C, Harvey BG, et al. Persistence of smoking-induced dysregulation of miRNA expression in the small airway epithelium despite smoking cessation. PLoS ONE. 2015;10: e0120824.

Article  PubMed  PubMed Central  Google Scholar 

Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 1998;339:1194–200.

Article  CAS  PubMed  Google Scholar 

Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med. 1996;153:1530–5.

Article  CAS  PubMed  Google Scholar 

Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, Pare PD. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:2645–53.

Article  CAS  PubMed  Google Scholar 

Oelsner EC, Balte PP, Bhatt SP, Cassano PA, Couper D, Folsom AR, Freedman ND, Jacobs DR Jr, Kalhan R, Mathew AR, et al. Lung function decline in former smokers and low-intensity current smokers: a secondary data analysis of the NHLBI Pooled Cohorts Study. Lancet Respir Med. 2020;8:34–44.

Article  PubMed  Google Scholar 

Oelsner EC, Smith BM, Hoffman EA, Folsom AR, Kawut SM, Kaufman JD, Manichaikul A, Lederer DJ, Schwartz JE, Watson KE, et al. Associations between emphysema-like lung on CT and incident airflow limitation: a general population-based cohort study. Thorax. 2018;73:486–8.

Article  PubMed  Google Scholar 

Bhatt SP, Bodduluri S, Hoffman EA, Newell JD Jr, Sieren JC, Dransfield MT, Reinhardt JM, Investigators CO. Computed tomography measure of lung at risk and lung function decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:569–76.

Article  PubMed  PubMed Central  Google Scholar 

Choi JY, Rhee CK. Diagnosis and treatment of early chronic obstructive lung disease (COPD). J Clin Med. 2020;9:3426.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou Y, Zhong NS, Li X, Chen S, Zheng J, Zhao D, Yao W, Zhi R, Wei L, He B, et al. Tiotropium in early-stage chronic obstructive pulmonary disease. N Engl J Med. 2017;377:923–35.

Article  CAS  PubMed  Google Scholar 

Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol. 2015;8:479–501.

Article  CAS  PubMed  Google Scholar 

Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013. https://doi.org/10.1002/14651858.CD010177.pub2.

Article  PubMed  PubMed Central  Google Scholar 

Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD009285.pub2.

Article  PubMed  PubMed Central  Google Scholar 

Koarai A, Sugiura H, Yamada M, Ichikawa T, Fujino N, Kawayama T, Ichinose M. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med. 2020;20:111.

Article  PubMed  PubMed Central  Google Scholar 

Bhatt SP, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Martinez FJ, Newby DE, Vestbo J, et al. Cigarette smoking and response to inhaled corticosteroids in COPD. Eur Respir J. 2018;51:1701393.

Article  PubMed  Google Scholar 

Tashkin DP, Celli B, Kesten S, Lystig T, Mehra S, Decramer M. Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J. 2010;35:287–94.

Article  CAS  PubMed  Google Scholar 

Tashkin DP, Goodin T, Bowling A, Price B, Ozol-Godfrey A, Sharma S, Sanjar S. Effect of smoking status on lung function, patient-reported outcomes, and safety among COPD patients treated with glycopyrrolate inhalation powder: pooled analysis of GEM1 and GEM2 studies. Respir Res. 2019;20:135.

Article  PubMed  PubMed Central  Google Scholar 

Sion KYJ, Huisman EL, Punekar YS, Naya I, Ismaila AS. A network meta-analysis of long-acting muscarinic antagonist (LAMA) and long-acting beta2-agonist (LABA) combinations in COPD. Pulm Ther. 2017;3:297–316.

Article  PubMed  PubMed Central  Google Scholar 

Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15–25.

Article  PubMed  Google Scholar 

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–22.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mammen MJ, Pai V, Aaron SD, Nici L, Alhazzani W, Alexander PE. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society clinical practice guideline. Ann Am Thorac Soc. 2020;17:1133–43.

Article  PubMed  Google Scholar 

Hsieh MJ, Chen NH, Cheng SL, Tao CW, Wei YF, Wu YK, Chan MC, Liu SF, Hsu WH, Yang TM, et al. Comparing clinical outcomes of tiotropium/olodaterol, umeclidinium/vilanterol, and indacaterol/glycopyrronium fixed-dose combination therapy in patients with chronic obstructive pulmonary disease in Taiwan: a multicenter cohort study. Int J Chron Obstruct Pulmon Dis. 2022;17:967–76.

Article  PubMed  PubMed Central